PriceTargets.com logo

Tectonic Therapeutic - TECX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $60.00
  • Forecasted Upside: 81.71%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$33.02 As of 10/4/2024 01:00 AM ET
▲ +3.34 (11.25%)

This chart shows the closing price for TECX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tectonic Therapeutic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TECX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TECX

Analyst Price Target is $60.00
▲ +81.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Tectonic Therapeutic in the last 3 months. The average price target is $60.00, with a high forecast of $76.00 and a low forecast of $49.00. The average price target represents a 81.71% upside from the last price of $33.02.

This chart shows the closing price for TECX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Tectonic Therapeutic.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/8/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/22/2024Wells Fargo & CompanyInitiated CoverageOverweight$55.00
7/24/2024Leerink PartnrsUpgradeStrong-Buy
7/24/2024Leerink PartnersInitiated CoverageOutperform$49.00
6/26/2024Piper SandlerInitiated CoverageOverweight$76.00
6/24/2024TD CowenInitiated CoverageBuy
(Data available from 10/6/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2024
  • 12 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2024

Current Sentiment

  • 12 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tectonic Therapeutic logo
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
Read More

Today's Range

Now: $33.02
Low: $29.69
High: $33.30

50 Day Range

MA: $19.93
Low: $16.06
High: $33.02

52 Week Range

Now: $33.02
Low: $12.12
High: $33.30

Volume

238,711 shs

Average Volume

39,291 shs

Market Capitalization

$1.48 billion

P/E Ratio

47.86

Dividend Yield

N/A

Beta

2.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Tectonic Therapeutic?

The following equities research analysts have issued research reports on Tectonic Therapeutic in the last year: Leerink Partners, Leerink Partnrs, Piper Sandler, TD Cowen, and Wells Fargo & Company.
View the latest analyst ratings for TECX.

What is the current price target for Tectonic Therapeutic?

3 Wall Street analysts have set twelve-month price targets for Tectonic Therapeutic in the last year. Their average twelve-month price target is $60.00, suggesting a possible upside of 81.7%. Piper Sandler has the highest price target set, predicting TECX will reach $76.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $49.00 for Tectonic Therapeutic in the next year.
View the latest price targets for TECX.

What is the current consensus analyst rating for Tectonic Therapeutic?

Tectonic Therapeutic currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TECX will outperform the market and that investors should add to their positions of Tectonic Therapeutic.
View the latest ratings for TECX.

What other companies compete with Tectonic Therapeutic?

Other companies that are similar to Tectonic Therapeutic include Cytokinetics, Krystal Biotech, Ultragenyx Pharmaceutical, Organon & Co. and BridgeBio Pharma. Learn More about companies similar to Tectonic Therapeutic.

How do I contact Tectonic Therapeutic's investor relations team?

Tectonic Therapeutic's physical mailing address is 100 TECHNOLOGY SQUARE 6TH FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is 617-914-8420 and its investor relations email address is [email protected]. The official website for Tectonic Therapeutic is www.avrobio.com. Learn More about contacing Tectonic Therapeutic investor relations.